Doximity heads into its Q4 FY2026 results today with short sellers meaningfully more aggressive and analysts broadly more cautious than they were just one month ago.
Short interest has become the defining positioning story. It rose 26% over the past month to 12.3% of the free float — a level that warrants attention for a health-care technology stock with a $4.9B market cap. The acceleration sharpened last week, with shares short climbing nearly 16% in five sessions. Despite that build, the borrow market remains loose: cost to borrow is a negligible 0.45%, and availability has eased dramatically from April peaks, when borrow was far tighter. The combination of rising short interest and cheap, plentiful borrow suggests bears are pressing their view with little friction — this is conviction-driven positioning, not a squeeze in the making.
Options traders are leaning the other way. The put/call ratio has pulled back to 0.57 — roughly 1.4 standard deviations below its 20-day average of 0.64 — indicating call activity is running above recent norms. That tilt toward calls arrives even as the stock shed 11.6% on Wednesday, extending a difficult week to a loss of nearly 9%. The divergence between a rising short base and elevated call activity captures the binary nature of the setup: one side is positioned for disappointment, the other for a bounce.
Analysts have been moving in one direction. Wells Fargo cut its target from $45 to $32 just three days ago while holding its Overweight rating. Goldman Sachs trimmed to $28 from $34 in early April, staying Neutral. Truist downgraded outright to Hold. The consensus mean target now sits at $37.55 — still 60% above the current price of $23.39 — but that gap reflects a series of reductions, not fresh optimism. The bull case rests on 10% revenue growth, record physician engagement, and expanding multi-module adoption among top clients. Bears point to gross margin compression to 91.5%, Q4 guidance implying only ~4% growth, and slowing net revenue retention among the top 20 clients — down to 112% — driven by pharma budgeting headwinds from policy uncertainty.
The print is therefore less a question of whether Doximity can grow and more a test of whether management can credibly reset the pharma exposure narrative and show that the engagement platform can sustain premium economics when its largest buyers are pulling back.
See the live data behind this article on ORTEX.
Open DOCS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
DOCS enters its fiscal Q4 2026 earnings report on May 13 carrying a heavy short position and a stock that has already been savaged — creating a setup where the bar may be low but the crowd is far from convinced. Short…
